BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $87 at RBC Capital
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $69.33 +3.49%
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
RBC Capital analyst Kennen MacKay lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $87.00 (from $89.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- BMO Capital Starts BioMarin Pharmaceutical Inc. (BMRN) at Outperform
- Morgan Stanley Downgrades Diamondback Energy (FANG) to Equalweight
- BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
